Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
Brett P. Monia(Ionis Pharmaceuticals (United States)), Doriano Fabbro(Novartis (Switzerland)), Thomas Geiger(Novartis (Switzerland)), Joseph F. Johnston(Ionis Pharmaceuticals (United States)), Marcel A. Müller(Sechenov University)
Cited by 453
Related Papers
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
|Nature|2013|2.1k
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k